Myths, Read Against the EvidenceArticle 18 of 27

Do GLP-1 peptides cause depression or suicidal thoughts?

THE REVIEW

On January 13, 2026, the FDA announced the results of a comprehensive review of 91 studies of GLP-1 receptor agonist peptides covering 107,910 patients.

The review didn't find an increased risk of suicidal ideation or behavior. The agency asked manufacturers to remove the warning from the labels of Saxenda, Wegovy, and Zepbound.

THE BACKUP DATA

The review followed earlier reports that came in once the peptides were on the market, the same reports that had prompted the warning in the first place.

The cardiovascular study of semaglutide (SELECT, about 17,600 people) also reported no increase in psychiatric side effects.

What this means

The popular conversation often misses both halves. "The warning was for nothing" misses that the review was prompted by real reports. "The warning was hidden truth" misses that the systematic review didn't find the signal.

The system worked. Signal arose, signal got reviewed, signal didn't replicate, warning is coming off.

← Previous

Do GLP-1 peptides cause thyroid cancer?

Do GLP-1 peptides cause infertility?

Related myths

Do GLP-1 peptides cause gallbladder problems?

Yes. And so does fast weight loss itself. This is a real safety topic.

Do GLP-1 peptides cause nausea?

Yes. And it's expected. Nausea is built into how this class of peptides works.

Do GLP-1 peptides cause thyroid cancer?

The boxed warning is based on rat studies. The human evidence so far doesn't show a population-level cancer effect. A specific high-risk subgroup is contraindicated.

Keep building trust

Move from the science to the proof, source, and practical questions.

Science next

What is GLP-1?

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Science next

Are all peptide sources the same? COAs, testing, and traceability

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Science next

Does a certificate of analysis prove a peptide is trustworthy?

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Practical questions

FAQ

Use the FAQ for logistics, safety boundaries, and common buyer questions.

Read the FAQ

References1 sources

See source line · 2026
U.S. Food and Drug Administration Drug Safety Communication, January 13, 2026. SELECT trial: Lincoff et al. 2023, *New England Journal of Medicine* (PMID 37952131).
Source line — see article body
PMID 37952131

Disclaimer. This article is for educational purposes only and does not constitute medical advice. Peptide signals and their therapeutic applications are complex and context-dependent.